OpenAI researcher Miles Wang is in talks to launch an AI-focused drug discovery startup that could reach a $2 billion valuation, according to multiple sources familiar with the fundraising discussions. The company would apply machine learning to accelerate pharmaceutical development and candidate identification.
Wang's departure from OpenAI signals growing momentum in applying large language models and AI systems to drug discovery, a field where computational approaches have struggled to meaningfully reduce development timelines. Traditional drug discovery takes 10 to 15 years and costs billions. AI-driven platforms promise to compress this timeline by automating molecular screening, predicting compound efficacy, and identifying promising drug candidates faster than conventional methods.
The $2 billion valuation reflects investor confidence in the space. Venture capital firms have backed multiple AI drug discovery companies in recent years, including Recursion Pharmaceuticals, Exscientia, and others. However, most remain pre-revenue or early-stage, betting that AI will eventually validate the approach by producing viable drug candidates that move through clinical trials.
Wang's involvement brings credibility. Researchers at OpenAI have published work on AI applications beyond large language models, and the company's computational infrastructure expertise translates directly to processing biological data at scale. A startup built by someone with his background could attract both top-tier talent and institutional capital.
The timing matters. Biotech investors face pressure to find the next wave of innovation. Gene therapies, CRISPR, and monoclonal antibodies delivered substantial returns, but pipelines are thinning. AI drug discovery offers a fresh narrative, even as evidence remains mixed on whether current systems deliver meaningfully better outcomes than existing computational chemistry approaches.
Success hinges on whether the startup can produce actual drug candidates that advance through preclinical testing and into human trials. Investor appetite runs high, but execution risk remains severe. The field has generated hype for years without generating